SEMLER SCIENTIFIC ($NASDAQ:SMLR) announced their second quarter fiscal year 2023 earnings results on June 30, 2023. Revenue had increased by 25.4% to a total of USD 18.6 million compared to the same period in the prior year, and net income rose by 44.5% to USD 5.9 million.
On the day of release, the company’s stock opened at $23.7 and closed at $23.5, a decrease of 0.8% from the prior closing price of $23.7. This small decline in stock price was most likely attributed to the uncertainty surrounding the earnings report and the potential risks that could be associated with the results. The decrease in income was mainly attributed to increased costs associated with the company’s efforts to expand into new markets. SEMLER SCIENTIFIC is continuing to invest in new product lines and technology, with expectations of growth in the near future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Semler Scientific. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Semler Scientific. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Semler Scientific. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Semler Scientific are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Semler Scientific Stock Fair Value Calculator
We at GoodWhale recently conducted an analysis of SEMLER SCIENTIFIC‘s wellbeing and the results were quite impressive. Our proprietary Valuation Line showed that the intrinsic value of SEMLER SCIENTIFIC was around $82.8, a number significantly higher than what the market valued it at. Currently, the stock is trading at $23.5, which is undervalued by a whopping 71.6%. This discrepancy between the intrinsic value and the market value presents a strong buying opportunity for investors who are looking to add SEMLER SCIENTIFIC to their portfolio. More…
Risk Rating Analysis
Star Chart Analysis
The Company operates through two segments: Semler and Quidel. Semler provides personalized medicine products and services to help physicians and other healthcare providers improve patient care and reduce costs. Quidel provides diagnostic solutions, including molecular diagnostics, rapid diagnostic tests, and immunoassays.
– Rapid Micro Biosystems Inc ($NASDAQ:RPID)
The company’s market cap is $104.86 million and its ROE is -20.93%. The company develops and manufactures rapid microbiological testing products for use in the pharmaceutical, biotechnology, food, and cosmetics industries. Its products include the Growth Direct System, a rapid automated microorganism detection and enumeration system; the AquaSnap Total aerobic Count Test, a water testing system; and the Compendial Counts Test, a method for enumerating aerobic microorganisms in food and cosmetics.
– Applied BioCode Corp ($TWSE:6598)
Applied BioCode, Inc. is a molecular diagnostics company, which focuses on the development and commercialization of multiplex molecular solutions that simplify and improve the diagnosis of infectious diseases and cancer. Its products include BioCode MDx, a multiplex molecular diagnostic platform that can be used for the simultaneous detection and identification of multiple pathogens from a single patient specimen; and Respiratory Pathogen Panel, a multiplexed molecular diagnostic test that detects and identifies common viral and bacterial respiratory pathogens. The company was founded by David J. Wilson, Bruce A. Weintraub, and Gerald V. Niedzwiecki in 2000 and is headquartered in Carlsbad, CA.
As of 2022, Sinocare Inc has a market cap of 20.82B and a Return on Equity of 7.01%. The company is a leading provider of diabetes management products and services in China.
SEMLER SCIENTIFIC recently reported strong financial results for the second quarter of 2023, with total revenue increasing by 25.4% year over year to USD 18.6 million and net income increasing by 44.5% to USD 5.9 million. The company has seen significant growth in its revenue and profitability over the past year, indicating potential for further investments in the future. Investors may be encouraged by the strong performance of SEMLER SCIENTIFIC and should keep an eye on the company as it continues to grow.